Methotrexate

Specifications

59-05-2CAS Number

200-413-8EC Number

(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acidIUPAC Name

C20H22N8O5Chemical Formula

454.4 g/molMolecular Weight

methotrexate; 59-05-2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Ledertrexate; Methylaminopterinum; Methotrexatum; Metotrexato; Antifolan; Rasuvo; Emtexate; L-Amethopterin; Amethopterine; NSC-740; Maxtrex; Farmitrexat; Medsatrexate; Methoblastin; Methotextrate; Methotrexat; Brimexate; Emthexat; Emthexate; Fauldexato; Lantarel; Lumexon; Metrotex; Novatrex; Otrexup; Tremetex; Trexeron; Trixilem; Texate; Metex; CL-14377; NCI-C04671; JYLAMVO; EMT 25,299; DTXSID4020822; NSC 740; CL 14377; YL5FZ2Y5U1; R 9985; REDITREX; NSC740; CHEBI:44185; ADX-2191; WR-19039; 4-amino-N(10)-methylpteroylglutamic acid; DTXCID80822; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid; R-9985; N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova; Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, L-; L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-; 4-Amino-N10-methylpteroylglutamic acid; Ebetrex; Metoject; Zlatal; Emtexate pf; Emtexate high-pot; (2S)-2-((4-((2,4-diaminopteridin-6-yl)methyl-methylamino)benzoyl)amino)pentanedioic acid; N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamic acid; Hydrate, Methotrexate; OTREXUP PFS; RefChem:6017; Metex 6013; Dicesium Salt Methotrexate; Methotrexate Methylaminopterin; L01BA01; L04AX03; GLUTAMIC ACID, N-(P-(((2,4-DIAMINO-6-PTERIDINYL)METHYL)METHYLAMINO)BENZOYL)-, L-(+)-; 4-Amino-4-deoxy-10-methylpteroyl-L-glutamic Acid; 4-AMINO-4-DEOXY-N(SUP 10)-METHYLPTEROYLGLUTAMATE; 4-AMINO-4-DEOXY-N(SUP 10)-METHYLPTEROYLGLUTAMIC ACID; N-(4-((2,4-Diaminopteridin-6-ylmethyl)(methyl)amino)benzoyl)-L-glutamic acid; 200-413-8; Methylaminopterin; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Mexate; MTX; 4-Amino-10-methylfolic acid; N-Bismethylpteroylglutamic acid; C20H22N8O5; Xatmep; Methotrexat-Ebewe; MFCD00064370; CHEMBL34259; TCMDC-125858; A-Methopterin; (2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid; N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid; NCGC00025060-04; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexate, L-; Methotrexate (hydrate); X 133; Metotressato [DCIT]; Metotressato; Metolate; MLS001401431; Methotrexatum [INN-Latin]; Metotrexato [INN-Spanish]; [3H]methotrexate; N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid; SMR000112001; [3H]-methotrexate; folic acid antagonist; CCRIS 1109; 4-Aminomethylpteroylglutamic acid; HSDB 3123; L-(+)-N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)glutamic acid; N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-(+)-glutamic acid; SR-01000075682; (+)-4-Amino-10-methylfolic acid; SMR000449324; EINECS 200-413-8; Methotrexate (1.0mg/mL in Methanol with 0.1N NaOH); UNII-YL5FZ2Y5U1; Nordimet; AI3-25299; Methotrexate RS; Extexate;; Maxtrex;; s1210; Intradose-MTX; Mexate;; 4-Amino-N(sup 10)-methylpteroylglutamic acid; Methotrexate CRS; Methylaminopterin;; 1dhi; 1dhj; 2drc; 4ocx; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid; CAS-59-05-2; MPI-2505; Prestwick_322; Otrexup (TN); Xatmep (TN); CL14377; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova [Czech]; Methylaminopterin; MTX; Methotrexate [USAN:USP:INN:BAN:JAN]; Spectrum_001836; Tocris-1230; 4kn0; Methotrexate (Standard); Prestwick0_000135; Prestwick1_000135; Prestwick2_000135; Spectrum2_001077; Spectrum3_000497; Spectrum4_000616; Spectrum5_000958; Abitrexate (Methotrexate); METHOTREXATE [MI]; N-(p-(((2,4-Diamino-6-pteridyl)methyl)methylamino)benzoyl)glutamic acid; METHOTREXATE [INN]; METHOTREXATE [JAN]; Epitope ID:230085; METHOTREXATE [HSDB]; METHOTREXATE [IARC]; METHOTREXATE [USAN]; N-(4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamicacid; NCIMech_000767; SCHEMBL3711; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova [Czech]; METHOTREXATE [VANDF]; BIDD:PXR0175; Lopac0_000020; KBioGR_001172; KBioSS_002341; METHOTREXATE [MART.]; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova; MLS000049968; MLS002154208; DivK1c_000114; METHOTREXATE [USP-RS]; METHOTREXATE [WHO-DD]; METHOTREXATE [WHO-IP]; SPBio_001094; SPBio_002149; Amethopterin (hydrate); CL14377 (hydrate); WR19039 (hydrate); cid_126941; cid_165528; GTPL4674; GTPL4815; orb1308506; orb3141220; SCHEMBL12421860; SCHEMBL23111732; SCHEMBL29349432; BDBM18050; BDBM66082; HMS500F16; KBio1_000114; KBio2_002338; KBio2_004906; KBio2_007474; KBio3_001493; Methotrexate (JP18/USP/INN); g301; NINDS_000114; Bio1_000486; Bio1_000975; Bio1_001464; GLXC-06696; HMS1568K12; HMS2095K12; HMS2233O18; HMS3260C21; HMS3414L09; HMS3678L07; HMS3712K12; METHOTREXATE [ORANGE BOOK]; METHOTREXATE [EP MONOGRAPH]; METHOTREXATE [USP IMPURITY]; APC-2002; MPI-5004; MSK10330; METHOTREXATE [USP MONOGRAPH]; Tox21_110944; Tox21_300269; Tox21_500020; CCG-35800; EBC-12158; EMT-25299; HY-14519R; METHOTREXATUM [WHO-IP LATIN]; STL535338; (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid; AKOS016340329; Tox21_110944_1; CS-1732; DB00563; KS-5093; LP00020; SDCCGSBI-0050009.P003; IDI1_000114; Methotrexate for peak identification CRS; SMP2_000020; NCGC00025060-01; NCGC00025060-02; NCGC00025060-03; NCGC00025060-05; NCGC00025060-06; NCGC00025060-07; NCGC00025060-08; NCGC00025060-09; NCGC00025060-10; NCGC00025060-11; NCGC00025060-12; NCGC00025060-13; NCGC00025060-15; NCGC00025060-16; NCGC00025060-18; NCGC00254216-01; NCGC00260705-01; HY-14519; EU-0100020; G-301; NS00098764; SW198601-3; Methotrexate 1.0 mg/ml in Dimethyl Sulfoxide; C01937; D00142; EN300-119523; F036492; Q422232; SR-01000597411; W-60383; SR-01000075682-1; SR-01000075682-2; SR-01000075682-6; SR-01000597411-1; BRD-K59456551-001-09-3; BRD-K59456551-001-11-9; BRD-K59456551-001-19-2; BRD-K59456551-001-20-0; BRD-K59456551-001-22-6; Methotrexate (1 mg/mL in Methanol with 0.1N NaOH); WLN: T66 BN DN GN JNJ CZ EZ H1N1&R DVMYVQ2VQ; Z1521553982; Methotrexate, European Pharmacopoeia (EP) Reference Standard; Methotrexate, United States Pharmacopeia (USP) Reference Standard; Glutamic acid,4-diamino-6-pteridinyl)methyl] methylamino]benzoyl]-, L-(+)-; L-Glutamic acid,4-diamino-6-pteridinyl)methyl]- methylamino]benzoyl]-; Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard; Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard; Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material; N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino]benzoyl]-L-glutamic acid; (2S)-2-((4-(((2,4-DIAMINOPTERIDIN-6-YL)METHYL)(METHYL)AMINO)BENZOYL)AMINO)PENTANEDIOIC ACID; (2S)-2-[[[4-[(2,4-diamino-6-pteridinyl)methyl-methylamino]phenyl]-oxomethyl]amino]pentanedioic acid;hydrate; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric acid;hydrate; (2S)-2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methyl-methyl-amino]phenyl]carbonylamino]pentanedioic acid;hydrate; 102613-64-9Synonyms